Webinar: Different Affiliate-Based Outsourcing Models for Regulatory Affairs
Often questions arise about the Affiliate-Based Outsourcing (ABO) Models for Regulatory Affairs:
1. How can it fit your specific needs?
2. How can it adapt to your organization and setup?
3. What are its possibilities of adjusting to your portfolio?
The purpose of this webinar is to share insights on the Regulatory Affairs Affiliate-Based Outsourcing Model’s flexibility and practical tips on how it can be tailored to your needs. We will share examples of different scenarios on how the ABO model can be customized to optimize costs and efficiently manage your local regulatory operations.
Expanding across Europe?
Make use of our experience. Explore your options in an informal chat with one of our experts.
This webinar focuses on learning:
- What are the options for the Affiliate-Based Outsourcing Model for Regulatory Affairs.
- What are the benefits of different models.
- What are the common challenges and how to overcome them.
- How to select the most beneficial Affiliate-Based Outsourcing Model for you.
Duration: 30 minutes
Speaker: Head of Regulatory Affairs, Olga Bernardova.
Olga Bernardova
Head of Regulatory Affairs
Other content that might interest you:
Biosimilars in the MENA Region: Regulatory Landscape
Regulatory affairs for biosimilars in Middle East North Africa (MENA) region are evolving as existing guidelines and regulatory frameworks are being updated. Since European Medicines Agency (EMA) introduced a legal pathway for biosimilars approval in 2004, several...
Successful Medical Device Registration in EAEU: New Legislation (Part 1)
Webinar: Successful Medical Device Registration in EAEU: New Legislation (Part 1) The webinar discusses and explains the basic, essential, and theoretical matters of the EAEU system, outlines the new approach to the quality, safety, and efficacy assessments, and...
Saudi FDA’s New Pricing Guidelines and Impact on the Region
In a highly evolving regional pricing environment, Saudi Arabia (KSA) is no exception. The Saudi Food and Drug Authority (SFDA) has been periodically reviewing its pricing mechanisms and criteria so that the country becomes a regional reference for the prices of pharmaceutical products. What followed is a change in the pricing strategy by SFDA and a shift from price takers to price makers.
